Early Notification and Brand Change Temozolomide Capsules
As advised via PHARMAC Tender Results of 29 March 2019 there is to be a change in the listing and future sole supply of Temozolomide Capsules.
New listing from 1 December 2019
Temaccord Caps 5 mg 5 capsule bottle pack Pharmacode 2388278 Schedule price $9.13
Temaccord Caps 20 mg 5 capsule bottle pack Pharmacode 2388251 Schedule price $16.38
Temaccord Caps 100 mg 5 capsule bottle pack Pharmacode 2388243 Schedule price $35.98
Temaccord Caps 140 mg 5 capsule bottle pack Pharmacode TBA Schedule price $50.12
Temaccord Caps 250 mg 5 capsule bottle pack Pharmacode 2388235 Schedule price $86.34
Incumbent brand and DELISTED 1 May 2020
Temozolomide Orion Caps 5 mg 5 capsule bottle pack Pharmacode 2505940 Schedule price $10.20
Temozolomide Orion Caps 20 mg 5 capsule bottle pack Pharmacode 2505959 Schedule price $18.30
Temozolomide Orion Caps 100 mg 5 capsule bottle pack Pharmacode 2505967 Schedule price $40.20
Temozolomide Orion Caps 140 mg 5 capsule bottle pack Pharmacode 2527162 Schedule price $56.00
Temozolomide Orion Caps 250 mg 5 capsule bottle pack Pharmacode 2505975 Schedule price $96.80
Temizole Caps 20 mg 5 capsule bottle pack Pharmacode 2527170 Schedule price $96.80
Reference pricing will not apply.
HSS (Hospital Supply Status) & CSS (Community Supply Status) commences 1 May 2020.
Brand Switch Fee not in notification.
As of the date of this notification ProPharma / PWR cannot accept Temozolomide Orion (all strengths) for credit under any circumstances.
From 1 December 2019 community pharmacies dispensing Temozolomide Capsules will need to support patients changing to the new brand and manage stock during the transition.
We would recommend you continue to purchase the incumbent and we will change automatically as existing stocks are exhausted.
You MUST manage your stock to avoid being caught with stock at the time sole supply commences 1 May 2020. Failure to do so may prove costly.
Once again we need your support to ensure stock in the supply chain moves through, to effectively ensure no losses are incurred by – supplier, wholesaler and pharmacy.
ProPharma / PWR will make a commercial decision in relation to stock holding which will potentially mean a change for pharmacy and patient. Unfortunately with the PHARMAC decision to have both products listed and fully funded until the commencement of the sole supply 1 May 2020 we need to act in the best interest of the company, pharmacy and patient. The patient will need to change , however wholesalers and pharmacy do not need to experience potential losses during the transition period.
Together we can make this a seamless and painless transition.
We thank you in anticipation of your ongoing support.